How much is a Vero stock worth?
One share of VERO stock can currently be purchased for approximately $1.49. How much money does Venus Concept make? Venus Concept has a market capitalization of $80.70 million and generates $78.01 million in revenue each year. The company earns $-81.71 million in net income (profit) each year or ($0.68) on an earnings per share basis.
Do institutions own Venus Concept (Vero) shares?
Do Institutions Own Venus Concept Inc. (NASDAQ:VERO) Shares? The big shareholder groups in Venus Concept Inc. ( NASDAQ:VERO ) have power over the company. Institutions will often...
What does Vero stand for?
TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13th-15th.
How many shares of Venus Concept stock are shorted?
Based on an average daily volume of 311,500 shares, the days-to-cover ratio is presently 1.7 days. Currently, 2.3% of the company's shares are sold short. View Venus Concept's Short Interest. When is Venus Concept's next earnings date? Venus Concept is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022.
Is Vero a good stock to buy?
The consensus among 1 Wall Street analyst covering (NASDAQ: VERO) stock is to Strong Buy VERO stock.
Should I buy Venus Concept stock?
There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Venus Concept stock.
When did Venus Concept go public?
December 22, 2020December 22, 2020 08:55 ET | Source: Venus Concept Inc.
Is VERO publicly traded?
(NASDAQ:VERO) stock earlier this year, a positive sign for shareholders.
What is Venus bliss?
Venus Bliss is an aesthetic machine used for fat cell destruction and fat reduction. It uses the proprietary technology of Venus Concept diode laser and (MP)2 technology to activate natural lipolysis. Venus Bliss is used to target problem areas such as the abdomen and flanks.
What is Venus versa?
Venus Versa™ is a medical aesthetic device that can target a wide range of aesthetic concerns using a combination of different clinical technologies. The system can deliver up to nine different treatments that address concerns from anti-aging and skin resurfacing, to hair removal and acne reduction*.
What is Venus Viva laser?
Venus Viva™ MD is a non-surgical solution for skin resurfacing that corrects signs of skin damage and improves the appearance of acne scars and other scars, stretch marks, rosacea, enlarged pores, deep wrinkles, and uneven skin texture and pigmentation.
Is Venus a publicly traded company?
Venus completed its initial public offering on February 11, 2021 with an offering of 4,600,000 units, at $10.00 per unit, generating gross proceeds of $46,000,000.
Who bought Venus?
Venus Concept Insider Transactions Over The Last Year Notably, that recent purchase by CEO & Director Domenic Serafino was not the only time they bought Venus Concept shares this year. They previously made an even bigger purchase of US$98k worth of shares at a price of US$2.46 per share.
Should I buy or sell Venus Concept stock right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Venus Concept in the last twelve months. There are currently 1 ho...
What is Venus Concept's stock price forecast for 2022?
1 brokerages have issued twelve-month price targets for Venus Concept's shares. Their forecasts range from $2.00 to $2.00. On average, they anticip...
How has Venus Concept's stock performed in 2022?
Venus Concept's stock was trading at $1.70 at the beginning of 2022. Since then, VERO stock has decreased by 62.2% and is now trading at $0.6418....
When is Venus Concept's next earnings date?
Venus Concept is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Venus C...
How were Venus Concept's earnings last quarter?
Venus Concept Inc. (NASDAQ:VERO) announced its quarterly earnings data on Monday, March, 28th. The company reported ($0.08) EPS for the quarter, be...
What guidance has Venus Concept issued on next quarter's earnings?
Venus Concept issued an update on its FY 2022 earnings guidance on Thursday, June, 9th. The company provided earnings per share guidance of for the...
Who are Venus Concept's key executives?
Venus Concept's management team includes the following people: Mr. Domenic Serafino , CEO & Director (Age 61, Pay $947.85k) ( LinkedIn Profile )...
Who are some of Venus Concept's key competitors?
Some companies that are related to Venus Concept include Invo Bioscience (IVOB) , Beyond Air (XAIR) , DarioHealth (DRIO) , Assure (ARHH) , Tac...
What other stocks do shareholders of Venus Concept own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Venus Concept investors own include Spectrum Pharmaceutica...
How much does Venus Concept make?
When is Venus Concept earnings call?
Venus Concept has a market capitalization of $133.55 million and generates $78.01 million in revenue each year. The company earns $-81,710,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.
Ideas
How can I listen to Venus Concept's earnings call? Venus Concept will be holding an earnings conference call on Friday, August 13th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13721406".
Profile
VERO starting to look bullish. I have outlined two targets that I will be looking at. LONG.
Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs
Venus Concept, Inc. develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related practice enhancement services.
Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing Programs CAMBRIDGE, Mass., Jan.
Verve Therapeutics Inc Insiders are Selling. Investors Should Take Notice
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 40th Annual J.P.
